Skip to main content

Table 1 Characterization of patients with HA who were positive for inhibitors

From: The IL-10 polarized cytokine pattern in innate and adaptive immunity cells contribute to the development of FVIII inhibitors

Patient number Age (years) Level of circulating FVIII Severity Historical peak of Bethesda titer (UB/mL) Bethesda titer (UB/mL) at the time of blood collection
1 11 2.0 Moderate 16.0 16.0
2 19 <1.0 Severe 3.2 0.0
3 35 <1.0 Severe 384.0 20.8
4 11 2.7 Moderate 12.8 8.4
5 14 <1.0 Severe 192.0 20.8
6 13 1.9 Moderate 5.8 5.8
7 40 <1.0 Severe 93.0 16.0
8 19 <1.0 Severe 160.0 12.0
9 27 <1.0 Severe 5.4 5.4
10 6 4.0 Moderate 14.4 6.4
11 37 1.8 Moderate 128.0 0.6
12 22 <1.0 Severe 288.0 115.2
13 31 <1,0 Severe 25.6 14.4
14 14 2.9 Moderate 36.0 5,2
15 8 1.0 Severe 384.0 4.6
16 16 <1.0 Severe 7.0 2.8
17 38 <1.0 Severe 48.0 0.3
18 8 2.8 Moderate 768.0 2.0
19 10 1.0 Severe 48.0 1.2
20 36 1.5 Moderate 13.0 0.0
21 14 <1.0 Severe 52.0 13.2
22 39 <1.0 Severe 3.9 0.0
23 1 1.6 Moderate 6.6 0.5
24 23 <1.0 Severe 224.0 1.4
25 57 <1.0 Severe 20.8 1.0